The most common sexually transmitted virus in the US is genital human papillomavirus (HPV) infection, with 20 million Americans currently infected and another 6.2 million becoming infected each year. Although HPV causes serious damage to women's health, including cervical cancer, awareness of the disease is surprisingly low.
In order to understand the public's knowledge, attitudes and beliefs regarding HPV and its vaccine, and to explore their preferences regarding receipt of HPV information, research was conducted with focus groups in 2003, just before the HPV vaccine was licensed for the public. The study's findings have been published online in the journal Health Education & Behavior, the official journal of the Society for Public Health Education, published by SAGE.
Researchers found that, not only was the HPV awareness and knowledge low, the STD-associated stigma served as a barrier to participants' acceptance to the future vaccine. "Although information about HPV's high prevalence and link to cervical cancer motivated participants to learn more about HPV, it also produced fear and anxiety," write the authors Allison L. Friedman, MS and Hilda Shepeard, MBA. "The research suggests that HPV education efforts must be approached with extreme caution. Instead of focusing on HPV as an STD, communications should take a public-health approach emphasizing the high prevalence and commonality of HPV infection among sexually active adults."
Source: SAGE Publications
Related stories:
Cervical cancer prevention should focus on vaccinating adolescent girls
The cost-effectiveness of vaccination in the United States against human papillomavirus (HPV), a sexually-transmitted virus that causes cervical cancer, will be optimized by achieving universal vaccine coverage in young adolescent girls, by targeting initial "catch-up" efforts to vaccinate women younger than 21 years of age, and by revising current screening policies, according to an analysis by Harvard School of Public Health (HSPH) researchers in the August 21, 2008 issue of
The New England Journal of Medicine.
NIST Trumps the Clumps: Making Biologic Drugs Safer
Scientists at the National Institute of Standards and Technology have developed a technique to measure the formation of clumps of proteins in protein-based pharmaceuticals. This first systematic study clarifies the conditions under which scientists can be assured that their instruments are faithfully measuring the formation of protein aggregates, a major concern because of its impact on quality control and safety in biologic drug manufacturing.
Study on government's controversial choice of HPV vaccine
The UK government may save up to £18.6 million a year by deciding to use the HPV vaccine Cervarix, given that it is equally effective as the more expensive Gardasil in preventing cervical abnormalities, according to a study published on BMJ.com today.
HPV linked to better survival in tonsil, tongue cancer
Researchers at the University of Michigan Comprehensive Cancer Center have found a series of markers that indicate which patients are more likely to survive cancers of the base of the tongue and tonsils.
Mothers less likely to pursue HPV vaccination for youngest daughters
Because the first national study of its kind has found that U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it’s incumbent upon the healthcare community to work to improve mom’s acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children’s Hospital Medical Center who conducted the study. HPV is a sexually transmitted virus known to cause cervical cancer.
FDA considers expanded use of HPV vaccine
Pharmaceutical manufacturer Merck & Co. Inc. said the U.S. Food and Drug Administration will consider expanding the use of its cervical cancer vaccine.
HPV vaccine reduces abnormal pap test results
In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine, according new research. The findings show the approved anti-HPV agent appears to prevent the development of cell changes that lead to cervical disease, said a researcher at the University of Alabama at Birmingham. The reduction in abnormal Pap results were presented at a conference Monday in Tampa.
Combination vaccine protects monkeys from ebola and Marburg viruses
An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys. Researchers from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) report their results today (Feb. 26) at the 2008 ASM Biodefense and Emerging Diseases Research Meeting in Baltimore, MD.